A novel anti-mouse CCR7 monoclonal antibody, C7Mab-7, demonstrates high sensitivity in flow cytometry, western blot, and immunohistochemistry

被引：0

作者：

Satofuka, Hiroyuki ^{[1
]}

Suzuki, Hiroyuki ^{[1
]}

Tanaka, Tomohiro ^{[1
]}

Ubukata, Rena ^{[1
]}

Hirose, Miu ^{[1
]}

Yamamoto, Haruto ^{[1
]}

Kaneko, Yu ^{[1
]}

Fujisawa, Shiori ^{[1
]}

Li, Guanjie ^{[1
]}

Kaneko, Mika K. ^{[1
]}

Kato, Yukinari ^{[1
]}

机构：

[1] Tohoku Univ, Grad Sch Med, Dept Antibody Drug Dev, 2-1 Seiryo-Machi,Aoba Ku, Sendai, Miyagi 9808575, Japan

来源：

BIOCHEMISTRY AND BIOPHYSICS REPORTS | 2025年 / 41卷

基金：

日本学术振兴会;

关键词：

Mouse CCR7; Monoclonal antibody; Cell-based immunization and screening; Flow cytometry; Western blot; Immunohistochemistry; CHEMOKINE RECEPTOR CCR7; LYMPH-NODE METASTASIS; EXPRESSION; INFILTRATION; FIBROCYTES; LEUKEMIA; CXCR4; CELLS;

D O I：

10.1016/j.bbrep.2025.101948

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

C-C chemokine receptor type 7 (CCR7) is a member of the G protein-coupled receptor family and functions as a lymph node-homing receptor for immune cells. Upon ligand binding, CCR7 promotes the migration of immune cells to secondary lymphoid organs. In cancers, CCR7 has been revealed as a critical molecule in lymph node metastasis. Consequently, anti-CCR7 monoclonal antibodies (mAbs) have been developed as cancer therapeutic agents. In this study, we established an anti-mouse CCR7 (mCCR7) mAb, C7Mab-7 (rat IgG1, kappa) using the Cell-Based Immunization and Screening (CBIS) method. C7Mab-7 demonstrated high sensitivity in flow cytometry. The dissociation constant (KD) value of C7Mab-7 was determined to be 2.5 x 10-9 M for mCCR7overexpressed Chinese hamster ovary-K1 (CHO/mCCR7) cells. Furthermore, C7Mab-7 detected mCCR7 with high sensitivity in western blot and immunohistochemistry. C7Mab-7, developed by the CBIS method, accelerates the development of CCR7-targeted antibody therapies and cancer diagnostics.

引用

页数：7

共 57 条

[1] Gattinoni L., Lugli E., Ji Y., Pos Z., Paulos C.M., Quigley M.F., Almeida J.R., Gostick E., Yu Z., Carpenito C., Wang E., Douek D.C., Price D.A., June C.H., Marincola F.M., Roederer M., Restifo N.P., A human memory T cell subset with stem cell-like properties, Nat. Med., 17, pp. 1290-1297, (2011)
[2] Clatworthy M.R., Aronin C.E., Mathews R.J., Morgan N.Y., Smith K.G., Germain R.N., Immune complexes stimulate CCR7-dependent dendritic cell migration to lymph nodes, Nat. Med., 20, pp. 1458-1463, (2014)
[3] Ben-Baruch A., The multifaceted roles of chemokines in malignancy, Cancer Metastasis Rev., 25, pp. 357-371, (2006)
[4] Honczarenko M., Glodek A.M., Swierkowski M., Na I.K., Silberstein L.E., Developmental stage-specific shift in responsiveness to chemokines during human B-cell development, Exp. Hematol., 34, pp. 1093-1100, (2006)
[5] Ben-Baruch A., Organ selectivity in metastasis: regulation by chemokines and their receptors, Clin. Exp. Metastasis, 25, pp. 345-356, (2008)
[6] Pesce S., Moretta L., Moretta A., Marcenaro E., Human NK cell subsets redistribution in pathological conditions: a role for CCR7 receptor, Front. Immunol., 7, (2016)
[7] Choi H., Song H., Jung Y.W., The roles of CCR7 for the homing of memory CD8+ T cells into their survival niches, Immune Netw, 20, (2020)
[8] Forster R., Davalos-Misslitz A.C., Rot A., CCR7 and its ligands: balancing immunity and tolerance, Nat. Rev. Immunol., 8, pp. 362-371, (2008)
[9] Brandum E.P., Jorgensen A.S., Rosenkilde M.M., Hjorto G.M., Dendritic cells and CCR7 expression: an important factor for autoimmune diseases, chronic inflammation, and cancer, Int. J. Mol. Sci., 22, (2021)
[10] Cuesta-Mateos C., Terron F., Herling M., CCR7 in blood cancers - review of its pathophysiological roles and the potential as a therapeutic target, Front. Oncol., 11, (2021)

← 1 2 3 4 5 6 →